learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
5 / 6 resultslearn sh-Polypeptide-7
learn Thymosin Beta 4
learn Stem Cell Factor
learn Overview
Research
5 / 1000+ results
research The Byzantine Logic of Patent Law Jurisprudence: Patent Protection for Dosage Regimes Revisited
UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.
research Court of Appeal Can Overrule Itself to Follow the EPO: UK Adopts EPO Stance on Second Medical Use Claims
The UK Court of Appeal ruled that new dosing regimens for drugs can be patented, aligning with the European Patent Office's approach.
research Recent European Legal Developments on Second Medical Uses and Dosage Regimes
European patent law now allows patents for new uses and dosages of known drugs, but protection scope is unclear.
research Generic Competition And Pharmaceutical Patent Strategies: A Sequel
The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.
research UK High Court Revokes Escitalopram Patent; Validity of Second Medical Use Claims Based on Dosage Regimes; Stay of Proceedings Pending EPO Opposition
The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.
Community Join
5 / 205 resultscommunity Brotzu lotion update
A new hair loss lotion by Dr. Brotzu, expected to regrow up to 5 years of lost hair, is set to be released by Fidia Farmaceutici. It claims to work like minoxidil and finasteride without side effects, but skepticism exists due to its classification as a cosmetic product.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community Dermatologist told me to quit fin after turning 40
A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.
community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.